Telefónica Selects Mavenir for Cloud-native IMS Core
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today confirms its selection by Telefónica Hispam (Hispanoamérica) to supply cloud-native IMS Core for fixed and mobile networks across Mexico, Colombia, and Chile.
As mobile networks continue to evolve, and to handle growing data and device needs, Mavenir’s cloud-native IMS platform serves as the foundational technology for 5G networks. The transition to automated, cloud-native IMS, will allow Telefónica Hispam to evolve all fixed and mobile voice services and modernize operations. The solution will be deployed on TCloud, Telefónica’s private telco cloud infrastructure.
Mavenir’s IMS is purpose-built for fully automated cloud environments, allowing Telefónica to operate with web-scale agility, ensuring 5G transformation is layered on existing 4G networks using a microservice-based architecture. Deploying zero-touch Continuous Integration, Continuous Deployment (CI/CD), containerized environments increase productivity and leverage current network investment with a 5G-ready, cloud-native IMS core platform.
Alejandro Ghianni, Planification and Engineering Director at Telefónica Hispam said, “At Telefónica, we appreciate that core network functions must be modernized to support network evolution, and virtualized architectures will need software that supports both VoLTE and 5G Voice. We are very excited to embark on this network transformation journey with Mavenir.”
Javier Gavilan, Mavenir’s Chief Technical Officer CALA region said, “Only a cloud-native network, evolved into a fully web-scale platform, can meet the requirements for a successful 5G transformation. Mavenir’s cloud-native IMS Core can be deployed on any cloud eliminating legacy hardware platforms. This mobile-first architecture has been deployed in a variety of large multivendor environments including O2 Telefónica in Germany and Virgin Mobile O2 in the UK. We are very pleased to have been awarded this important project by Telefónica Hispam.
“Mavenir is the global leader in cloud-native mobile network software applications, supporting over 3 billion subscribers worldwide. Mavenir’s modernized, software-based approach transforms mobile communications networks, to operate in a fully virtualized environment, where devices, applications, and services can run on an automated network utilizing open architectures, containers, and artificial intelligence,” concluded Gavilan.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Telefónica Hispam:
Telefónica is one of the largest telecommunications service providers in Spanish America. The company operates under the Movistar trademark and offers fixed broadband connectivity services -with FTTH solutions- and mobile with 4G networks, as well as a wide range of digital services for more than 109 million residential and business customers in the region. Telefónica Hispam offers its services in: Mexico, Colombia, Venezuela, Peru, Ecuador, Uruguay, Chile and Argentina.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005163/en/
Contact information
Mavenir PR Contacts:
PR@mavenir.com
Emmanuela Spiteri
Telefónica Hispam PR Contacts:
dulce.jimenez@telefonica.com
Dulce Jiménez
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Climate Impact X Launches CIX Exchange to Level up Carbon Market Transparency, Certainty and Liquidity8.6.2023 03:00:00 EEST | Press release
Climate Impact X (CIX), a global marketplace, auctions house and exchange for trusted carbon credits, has successfully launched its spot trading platform, CIX Exchange, completing the company’s core solutions suite with three operational venues. Powered by Nasdaq's trading technology, CIX Exchange offers carbon market professionals a customised experience built on international best practices for platform stability, performance and governance. Users can efficiently discover market-driven prices, compare individual projects and trade standard contracts. To address industry calls for greater transparency and price certainty, CIX has introduced the first daily on-exchange liquidity window in the voluntary carbon market with firm bids and offers. This dedicated 30-minute pricing session pools all-day liquidity from Asia, Europe and Middle East to help sharpen benchmark prices and improve order depth for spot nature-based credits. By close of trading on 7 June 2023, bids and offers had conv
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom